Clinical Development of RSO-021, a Novel Covalent Inhibitor Targeting Mitochondrial PRX3
Time: 3:30 pm
day: Conference Day Two
Details:
- What is the optimal profile of a covalent drug targeting PRX3, considering target engagement, PKPD, safety and tolerability?
- How to design and implement clinical trials to validate the safety, efficacy, and specificity of covalent modification strategies and with what biomarkers?
- How to predict and mitigate the long-term effects and potential for cumulative toxicity of covalent drugs in patients?
